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Abstract
Assessing vaccine coverage is an essential component of vaccine programme monitoring and evaluation. Vaccine coverage data are available
in EU/EEA countries at both national and subnational levels and are used for programmatic purposes at any level. European-wide data
collection is performed by WHO through the Centralized Information System for Infectious Diseases, as part of the global data collection
jointly conducted with UNICEF. Data quality and comparability are still challenging at an international level. According to available
information, vaccination registries are available in 11 countries in the EU/EEA, but only in ﬁve countries do they have national coverage. In
2012 ECDC, through the VENICE II network, started the European Vaccination Coverage Collection System (EVACO project), with the
ﬁnal aim of improving the quality of vaccine coverage data at EU level, by deﬁning and implementing standards.
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What Is Vaccination Coverage?
Vaccination coverage can be deﬁned as the number of persons
belonging to a certain population (i.e. one birth cohort, a group
targeted by vaccination campaigns, etc.) vaccinated against a
speciﬁc disease, divided by the total number of individuals
belonging to the same population. Such an apparently easy
parameter is actually very tricky both to deﬁne and to assess
adequately.
Several methods have been developed to assess vaccination
coverage.
1. Administrative methods that are based on routine estimates
of administered vaccine doses divided by the total estimated
number of people in the target population. Administrative
method estimates can be severely affected by inaccurate
numerators or denominators.
2. Surveys: different survey designs have been developed to
estimate the levels of immunization coverage at either
national or subnational level, or even in selected population
groups. Those are usually intended to provide coverage
estimates that can be used to verify data collected by
administrative methods and eventually to provide additional
information that is not available with administrative systems.
Several different methodologies have been developed to
conduct such surveys [1].
3. Seroprevalence surveys are designed to assess the actual
level of immunity against a speciﬁc infectious disease.
Serological surveys cannot distinguish between protection
due to vaccination and naturally acquired immunity, and
cannot estimate or verify vaccination coverage. In addition,
they can be useful only when a clear correlate of protection
from the disease is available after serology testing.
4. Immunization registries (immunization information systems):
population-based, computerized registries, including individ-
ual records about all the residents within a certain area, can
be used for assessing vaccination coverage. Immunization
information systems are very useful tools to implement
vaccination programmes and sustain high vaccination cover-
age; on the other hand, they are not extensively used for
assessing vaccination coverage. Strengths and weaknesses of
each methodology are summarized in Table 1.
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Potential Issues That May Affect Vaccine
Coverage Assessment
Methods used for deﬁning vaccination coverage can affect the
outcome. As an example, measles vaccination coverage can be
deﬁned as ‘the percentage of 1-year-olds who have received at
least one dose of measles containing vaccine in a given year’ [2].
According to this deﬁnition, the statement ‘95% measles
coverage in 2012 in country X’ suggests that 95% of children
living in country X in 2012 received one dose of measles vaccine
before their 1st birthday. This looks apparently simple; never-
theless there are different options for assessing vaccination
coverage using the deﬁnition above. The denominator should
include children between 1 and 12 months of age living in
country X in 2012; the numerator should account for those
children among the population included in the denominatorwho
received one dose of measles vaccine. If a one-point survey is
used to assess vaccine coverage, then the numerator will report
on the number of vaccinated children living in country X in 2012.
In contrast, if an administrative method is used, very likely only
those children vaccinated in 2012 will be counted (or even
measles vaccine doses distributed in 2012), and children who
were still 12 months old in 2012 but who received their measles
vaccination in 2011 will not be included in the numerator. This is
not a trivial issue and represents only one of the potential
problems related to the way vaccination coverage is deﬁned. A
correct deﬁnition of both numerator and denominator is
essential for allowing comparison and interpretation of coverage
data, as well as methodology used for the assessment.
Unfortunately, not only methodological issues can affect
vaccination coverage assessment. In fact both numerator and
denominator ascertainment could be severely biased. In the
absence of a good information system, the denominator (i.e.
the target population) can be underestimated because of the
presence of uncensored population groups. This can be the
case of illegal immigrants or travelling communities not
captured by the system. On the other hand, the denominator
can be overestimated because of the presence of emigration
ﬂows that are not promptly communicated and registered; for
this reason, people no longer residing in the area may be still
counted in the denominator and will dilute the coverage
estimate. Similarly, ascertainment of vaccination status (numer-
ator) could represent a challenge; lack of documentation of
past vaccinations is one of the most frequent issues. Moreover,
vaccine coverage assessment can be particularly challenging
after supplementary immunization activities; in this speciﬁc
case it is common to observe vaccination coverage levels
>100%, because the number of distributed doses is often
higher than the targeted population (i.e. children out of the
targeted age groups are vaccinated).
Why Vaccination Coverage Assessment Is
Important
Vaccination, more than any other public health intervention, has
not only an intrinsic value for the individual but also a great value
for society. Beneﬁcial externalities linked to vaccination pro-
grammes are related not only to the indirect protection effect,
which non-immune people could beneﬁt from, but also to
broadersocietalbeneﬁts intheformofhigherproductivity (fewer
working days lost), better education (lower school absenteeism)
and economic gain (in the case of a positive cost–beneﬁt ratio).
Traditionally, vaccines are used in the framework of a broad
programme including planning, implementation and evaluation.
Vaccine coverage is one of the primary output indicators of
vaccination programmes: programme goals are usually
expressed in terms of vaccine coverage levels (i.e. >90%,
>95%, etc.) and a drop in vaccination coverage should lead to
an urgent reaction by public health. More than the number of
vaccinated individuals, what counts is the proportion of the
TABLE 1. Strengths and weaknesses of different methodol-
ogies for assessing vaccination coverage
Method Strengths Weaknesses
Administrative
methods
Based on routine collection,
provide robust series
of data.
Integrated in the vaccination
programme, do not require
ad hoc implementation.
Not expensive.
Can be severely affected by
inaccurate numerator and/
or denominator.
Do not provide individual
data if only number of
administered doses is
reported.
Surveys Useful to assess data
collected through
administrative methods.
Are the only source of
information if administrative
systems are not in place.
Can provide additional
information, i.e. on reasons
for missed vaccination.
Can be integrated into surveys
with broader scope (nutrition,
child health, education, etc.).
Require ad hoc
implementation.
Require ad hoc resources.
Seroprevalence
surveys
Can provide information on
the actual level of immunity
in the target population.
Extremely useful in population
subgroups that are likely
to be missed by
administrative
methods (hard-to-reach).
Impossible to distinguish
between vaccination-
acquired and naturally
acquired immunity.
Are suitable only when a
clear serological correlate
of protection is available.
Expensive.
Immunization
registries
Can provide very precise,
individual information on
immunization status.
Can be linked to other health
data sources for assessing
other aspects of vaccination
programme (safety,
effectiveness, impact, etc.).
Are designed for improving
service delivery (reminder
systems, schedule
compliance, etc.) more
than providing vaccine
coverage data.
Estimates are strongly
affected by the coverage
of the registry.
Are implemented at
national level in few
countries so far.
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population that is vaccinated, namely the vaccination coverage;
this is particularly important when herd immunity is expected
as a positive effect of the vaccination, as is the case for most
vaccination programmes. In fact, vaccination coverage esti-
mates provide public health professionals with important
information on both the level of protection of the community
as a whole and the potential presence of pockets of susceptible
individuals. Such information is particularly important for
designing and implementing tailored intervention, i.e. in speciﬁc
geographical areas or particular age groups. Last but not least,
vaccination coverage is a very good indicator for allowing
benchmarking at local, national and international level. In this
respect, standardization of methods for vaccination coverage
assessment is paramount. International benchmarking can also
be used to raise awareness on the quality of the vaccination
programme and for highlighting gaps and challenges.
Which Coverage Data Are Available in
Europe (EU Level, National and Local
Level) and Problems Related to Data
Quality
Vaccination coverage is assessed in every district or region in
the EU. Unfortunately, both the methods used and the
frequency of assessment are highly variable, making compar-
ison and benchmarking challenging. This has been one of the
most important ﬁndings of the survey conducted by the
VENICE network in 2007 in 27 EU/EEA member states [3].
According to the results from the VENICE survey, time
intervals used for assessment range widely (from 1 month to
5 years); moreover, vaccination coverage is assessed either at
12 months, or at 24 months, or at age of school entry. The
report also demonstrates that vaccination coverage data are
validated in about half of the countries.
Vaccination coverage in EU countries is estimated using
diverse methods. Administrative methods are most commonly
used but a wide variety of parameters are used for assessment,
including the number of subjects vaccinated, the number of
vaccines administered, the number of vaccines distributed or
collection of data from vaccination points like schools or
well-baby clinics. Moreover, surveys are frequently used to
validate administrative data collection, in the form of inter-
views, focus groups and household or school surveys [3]. Use
of computerized systems will be discussed later in this paper.
The only system currently in place for collecting vaccination
coverage data at international level is run jointly by WHO and
UNICEF [4]. All countries, including the EU member states,
are asked yearly to ﬁll in the WHO/UNICEF Joint Reporting
Form on Immunization [5]. The Joint Reporting Form is a
complex tool that aims at collecting data and elaborating
indicators for monitoring and evaluating vaccination pro-
grammes. To improve the quality and assure comparability of
data, WHO and UNICEF report a vaccine coverage estimate
based on the information included in the Joint Reporting Form
after applying a complex algorithm [6]. According to this
algorithm, if multiple ﬁgures are available for a given country,
an effort is made to create a consistent pattern over time from
the data source that has the least potential for bias. Interpo-
lation is used to assign values for years for which data are not
available. If there are no data available for the most recent
estimation period, the estimate will stay the same as in the
previous year. Notes are added to the published data to better
explain how the data were reported but in some cases they
are not enough to understand all the ﬁgures.
Based on data reported in the Joint Reporting Form, the
Centralized Information System for Infectious Diseases (CI-
SID) is the system used by WHO to collect, analyse and
present data on vaccination coverage in the European region
[7]. Due to the methodological issues discussed above,
occasionally the ﬁgures on vaccination coverage presented
by CISID are not the same as the ﬁgures presented on the
WHO general website, which poses another difﬁculty in
interpreting these data [8,9]. Even though the reliability of
these data is still a challenge, nevertheless WHO CISID is the
only robust source for comparing vaccination coverage in the
EU at present (Table 2). To improve data quality, international
standards should be agreed by Member States and compliance
to the reference standard should be part of regular monitor-
ing. This is still a challenge in Europe, where implementation
of vaccination programmes is the exclusive task of the national
authorities. The large variety of delivery systems and vacci-
nation schedules makes developing EU standards very difﬁcult.
How Available Vaccine Coverage Data Can
Be Used
Vaccine coverage data could be used not only for monitoring
the quality of vaccination programmes but also for identifying
and prioritizing targeted interventions. In fact, gaps in the
immunity in selected population groups (geographical areas,
speciﬁc age groups, hard-to-reach communities, etc.) can be
identiﬁed by means of a thorough analysis of vaccination
coverage data. In the presence of good quality data, vaccination
coverage can provide good estimates of the real level of
immunity in the population, as further discussed in this paper.
In contrast, when vaccination coverage data are not reliable,
only seroprevalence studies can identify immunity gaps and
inform targeted actions [10].
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 5), 7–11
CMI Lopalco and Carrillo Santisteve Immunization coverage assessment in Europe 9
Availability of relatively long time series of vaccine coverage
data can provide a rough estimate of the susceptible population
that accumulated over a certain period. As an exercise,
vaccination coverage data reported to WHO by France have
been used to estimate the population that was susceptible to
measles in 2011. Based on number of unvaccinated children,
not accounting for natural boosters and estimating vaccine of
95% after one vaccine dose, the size of susceptible population
per age group has been estimated (Fig. 1).
Number of measles cases reported in France during the
outbreak that occurred in 2011, distributed by age group (data
reported to ECDC Tessy [11]), are shown in Fig. 2.
Even being the result of a very rough estimate, the
distribution of cases reported during the large outbreak in
2011 ﬁts very well with the distribution of the estimated
susceptible population. Deﬁnitively, in the presence of robust
vaccination coverage data, some disease forecast can be
performed without using sophisticated modelling. In particular,
population immunity gaps could be identiﬁed and addressed by
speciﬁc supplementary immunization activities.
Vaccine Coverage Versus Seroprevalence
Data
Well-designed, well-conducted seroprevalence surveys are the
best tool to assess the real immunological status of the
population and identify immunity gaps. In addition, factors
predicting low coverage can be identiﬁed and waning immunity
can be explored [1,12]. In the presence of low circulation of the
infectious agent, seroprevalence data can be a good proxy of the
vaccination coverage and, at least, validate data collected
through vaccine coverage surveys or administrative methods.
On the other hand, serosurveys are expensive and their routine
use is limited. Moreover, in the presence of good-quality vaccine
coverage data, the value-added of serosurveys for informing
vaccination programmes is limited [12]. Combining these to
wide-scope studies (health interviews/surveys during childhood
or adolescence) or using lower-cost methodologies (use of
residual sera) could optimize the use of resources and make
them more suitable for public health purposes.
Vaccination Registries in Europe
Vaccination registries, better deﬁned as Immunization infor-
mation systems, are computerized databases that record each
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FIG. 1. Estimate of the population susceptible to measles in France in
2011, based on vaccine coverage data reported in Centralized
Information System for Infectious Diseases; assuming vaccine efﬁcacy
of 95% after one dose and not taking into account the effect of
potential natural boosting.
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FIG. 2. Number of measles cases reported in France in 2011. Source
ECDC/Tessy (The European Surveillance System).
TABLE 2. Vaccine coverage data available at international
level
WHO/Europe’s centralized
information system for
infectious diseases (CISID)
WHO/Europe’s programme on vaccine-
preventable diseases and immunization collects
data on vaccination coverage in each Member
State. These data are collected annually, using
the WHO/United Nations Children’s Fund
(UNICEF) joint reporting form (JRF).
Source: Country national coverage reports and
WHO/UNICEF coverage estimates. Data
reported are the result of an estimate based
on a tailored algorithm.
WHO/UNICEF estimates of
national immunization
coverage at global level
The most likely true level of immunization
coverage is estimated and reported annually,
based on data ofﬁcially reported to WHO
and UNICEF by Member States as well as
data reported in the published and grey
literature. Whenever possible local experts
have also been consulted for additional
information regarding the performance of
speciﬁc local immunization services.
ECDC/VENICE annual survey
on inﬂuenza vaccination
Since 2007, ECDC has organized an annual
survey—conducted by the VENICE project
—on seasonal inﬂuenza coverage.
Information on how inﬂuenza vaccination
programmes are organized in the EU is
also available.
ECDC/VENICE EVACO
project
ECDC, through the VENICE network, started in
2011 the European Vaccine Coverage Project
(EVACO). Main aim of the project is to provide
reliable and standardized vaccine coverage data
in the EU. A standard for data collection has
been agreed and a piloting phase has been
concluded. Discussion is ongoing on integration
of EVACO into the CISID system.
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vaccine dose provided to persons resident in a deﬁned area.
They represent a very powerful tool both at the vaccination
point of care and at population level. Locally they support
many operational aspects of the vaccination programme, like
managing recall/reminding systems, monitoring safety of
administered vaccines, managing vaccine stocks, etc. At a
population level, immunization information systems provide
information (ﬁrst of all vaccination coverage) useful for
identifying gaps and improving vaccination coverage. Privacy
and conﬁdentiality are an essential aspect of immunization
information systems. Data must be protected and treated as
sensitive information. Policies and guidelines on data conﬁ-
dentiality are available in Europe [1,13].
A description of immunization registers in six European
countries has been published by Pebody [14]. Additionally,
according to a recent VENICE survey conducted in 24 EU/EEA
member states, immunization information systems are avail-
able in 11 countries but only in ﬁve countries do they have
national coverage. Nevertheless, the situation is rapidly
evolving as a further nine countries reported an intention to
implement immunization information systems in the near
future [1].
Conclusions
Assessing vaccine coverage is an essential component of
vaccine programme monitoring and evaluation. At present,
CISID is the only reliable source of robust vaccine coverage
data at a European level. Nevertheless, lack of standards for
data collection and reporting prevents international compar-
ison and benchmarking.
In 2012 ECDC, through the VENICE II network, started the
European Vaccination Coverage Collection System (EVACO
project), with the ﬁnal aim of improving the quality of vaccine
coverage data at an EU level, by deﬁning and implementing
standards. This represents the ﬁrst attempt at an EU level to
improve vaccine coverage data quality and encourage the
adoption of standards for data collection. According to the
preliminary pilotingof theproject, outof 29 invited EUcountries,
25 were able to provide data according to the EVACO standard.
Nineteen countries also reported data at a subnational level
(EVACO preliminary results, personal communication with P.F.
D’Ancona). Thereby preliminary results were promising. During
the implementation phase of the EVACO project integration
with the CISID system will be carefully considered to avoid
duplication and beneﬁt of synergies.
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